ArticleCanadian journal of psychiatry. Revue canadienne de psychiatrie2021
Are There Therapeutic Benefits of Cannabinoid Products in Adult Mental Illness?
Article in Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Pharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis.The International journal on drug policy · 2021Pooled it
- Perceptions of cannabis among adults aged 60 years and older in Canada: a qualitative study.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2025Article
- Mental and Physical Health-Related Cannabis Motives Mediate the Relationship between Childhood Trauma and Problematic Cannabis Use over Time among Emerging Adult Cannabis Users.Substance use & misuse · 2024Article
- Youth cannabis use in Canada post-legalization: service providers' perceptions, practices, and recommendations.Substance abuse treatment, prevention, and policy · 2023Article
- Tourette syndrome: clinical features, pathophysiology, and treatment.The Lancet. Neurology · 2023Review
- Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing.Frontiers in pharmacology · 2023Article
- Response to Canadian Psychiatric Association Cannabinoid Products Position Statement: Potential for Ameliorating Cannabis Withdrawal.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2021Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A position statement developed by the Canadian Psychiatric Association's (CPA) Research Committee and approved by the CPA's Board of Directors on May 13, 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.